ARQT
HEALTHCAREArcutis Biotherapeutics Inc
AI Insight
What's Moving ARQT Today?
No stock-specific AI insight has been generated for ARQT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$13.06$31.77
$27.34
Fundamentals
Market Cap$3.3B
P/E Ratio—
EPS$-0.02
Dividend Yield—
Dividend / Share—
ROE-1.4%
Profit Margin-0.6%
Debt / Equity—
Trading
Volume168K
Avg Volume (10D)—
Shares Outstanding125.1M
ARQT News
26 articles- Arcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65%Motley Fool·Jun 23, 2026
- Insider Sell Alert: Sue-jean Lin Sells Shares of Arcutis Biotherapeutics Inc (ARQT)GuruFocus·Jun 18, 2026
- [144] Arcutis Biotherapeutics, Inc. SEC FilingStock Titan·Jun 16, 2026
- Is Arcutis (ARQT) Using Genital Psoriasis Education to Quietly Reshape Its Dermatology Strategy?Yahoo Finance·Jun 12, 2026
- Is Arcutis Biotherapeutics (ARQT) Quietly Redefining Its Risk Profile With ZORYVE Momentum And New Guidance?Simply Wall Street·Jun 11, 2026
- Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive StatusMarketbeat·Jun 10, 2026
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Jun 5, 2026
- New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical DermatologyYahoo Finance·Jun 3, 2026
- Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare ConferenceYahoo Finance·May 26, 2026
- Arcutis Biotherapeutics (ARQT) officer sells 222 shares to cover RSU taxStock Titan·May 14, 2026
- Arcutis (ARQT) CFO tax-related sale of 435 shares after RSU vestingStock Titan·May 13, 2026
- Arcutis Biotherapeutics (ARQT) Is Down 11.0% After Strong Q1 And sNDA For ZORYVE ExpansionYahoo Finance·May 9, 2026
- Arcutis Biotherapeutics, Inc. Q1 2026 Earnings Call SummaryMoby·May 7, 2026
- Arcutis Biotherapeutics Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 6, 2026
- Arcutis Announces First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 6, 2026
- PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseYahoo Finance·Apr 30, 2026
- Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should KnowYahoo Finance·Apr 29, 2026
- Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 MonthsYahoo Finance·Apr 27, 2026
- A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price MovesYahoo Finance·Apr 24, 2026
- How The Arcutis Biotherapeutics (ARQT) Narrative Is Shifting Around Zoryve And The $35 TargetYahoo Finance·Apr 23, 2026
- Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis GuidelinesYahoo Finance·Apr 22, 2026
- Arcutis Biotherapeutics (ARQT) Presents Positive Phase 2 Data for ZORYVE Cream in InfantsYahoo Finance·Apr 19, 2026
- Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026GlobeNewswire Inc.·Apr 15, 2026
- Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow PositiveMarketbeat·Apr 15, 2026
- Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should KnowThe Motley Fool·Apr 8, 2026
All 26 articles loaded
Price Data
Open$26.46
Previous Close$26.27
Day High$27.50
Day Low$26.46
52 Week High$31.77
52 Week Low$13.06
52-Week Range
$13.06$31.77
$27.34
Fundamentals
Market Cap$3.3B
P/E Ratio—
EPS$-0.02
Dividend Yield—
Dividend / Share—
ROE-1.4%
Profit Margin-0.6%
Debt / Equity—
Trading
Volume168K
Avg Volume (10D)—
Shares Outstanding125.1M
About Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company is headquartered in Westlake Village, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—